Paper36927642
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.
Hellmich B and 26 others. Ann Rheum Dis, 2024. Cited by 603 papers, by iCite.
Cite this record
ConductScience Library. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Papers, record 36927642. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36927642
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Major topic |
| Granulomatosis with Polyangiitis | Major topic |
| Microscopic Polyangiitis | Major topic |
| Humans | |
| Antibodies, Antineutrophil Cytoplasmic | |
| Azathioprine | |
| Cyclophosphamide | |
| Remission Induction | |
| Rituximab | |
| Practice Guidelines as Topic |
Source PubMed
Trials4
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT06226662 | Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) | Background | ClinicalTrials.gov | |
| NCT06590545 | Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis | Results | ClinicalTrials.gov | |
| NCT06611696 | Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis | Results | ClinicalTrials.gov | |
| NCT07815886 | Benralizumab Effectiveness in EGPA | Results | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 38040572 | Reply. | https://conductscience.org/library/papers/38040572 |
Source PubMed
Cited by446
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 603 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42979116 | Eosinophils in autoimmune diseases: context-dependent pathogenesis, functional heterogeneity, and therapeutic translation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42979116 | PubMed |
| 42975756 | Low-dose IL-2 therapy in autoimmune diseases: mechanisms, clinical evidence, and future strategies for precision immune regulation. | Clin Rev Allergy Immunol | 2026 | https://conductscience.org/library/papers/42975756 | PubMed |
| 42963439 | Association between baseline systemic immune-inflammation index and subsequent stroke in ANCA-associated vasculitis. | Clin Rheumatol | 2026 | https://conductscience.org/library/papers/42963439 | PubMed |
| 42957252 | Hepatobiliary Adverse Events Associated With Avacopan: Analysis of the JADER Database. | In Vivo | 2026 | https://conductscience.org/library/papers/42957252 | PubMed |
| 42944789 | Baseline neutrophil-to-HDL cholesterol ratio is associated with subsequent cerebrovascular accident in patients with microscopic polyangiitis or granulomatosis with polyangiitis. | Clin Rheumatol | 2026 | https://conductscience.org/library/papers/42944789 | PubMed |
| 42924604 | Inflammatory regulatory mechanisms and targeted therapy of antineutrophil cytoplasmic antibodies in atherosclerosis (Review). | Int J Mol Med | 2026 | https://conductscience.org/library/papers/42924604 | PubMed |
| 42909277 | A critical appraisal of guidelines and recommendations for the management of ANCA-associated vasculitis. | Clin Kidney J | 2026 | https://conductscience.org/library/papers/42909277 | PubMed |
| 42898620 | Early recognition of eosinophilic granulomatosis with polyangiitis in outpatient settings: musculoskeletal and gastrointestinal clues beyond respiratory disease. | Front Immunol | 2026 | https://conductscience.org/library/papers/42898620 | PubMed |
| 42898067 | Phenotypic characterization of patients with ANCA-associated vasculitis and diffuse alveolar hemorrhage: a data-driven analysis of a multicentre, retrospective, nationwide cohort. | Ann Intensive Care | 2026 | https://conductscience.org/library/papers/42898067 | PubMed |
| 42890987 | Isolated Acute Tubulointerstitial Nephritis in a Myeloperoxidase-ANCA-Positive Patient Without Crescentic Glomerulonephritis. | Cureus | 2026 | https://conductscience.org/library/papers/42890987 | PubMed |
| 42882256 | Prostatic Involvement in Granulomatosis with Polyangiitis: A Case Report and Scoping Review. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42882256 | PubMed |
| 42876531 | Anti-interferon-γ autoantibodies: immunopathogenesis, diagnostic innovation, and emerging therapeutic strategies in an adult-onset immunodeficiency. | Front Immunol | 2026 | https://conductscience.org/library/papers/42876531 | PubMed |
| 42872282 | Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody Vasculitis With Isolated Renal Presentation in an Older Female Patient: A Diagnostic and Therapeutic Challenge. | J Med Cases | 2026 | https://conductscience.org/library/papers/42872282 | PubMed |
| 42857311 | Early experience of avacopan for ANCA-associated vasculitis in an Australian paediatric population: a case series. | EULAR Rheumatol Open | 2026 | https://conductscience.org/library/papers/42857311 | PubMed |
| 42844361 | Next-generation immune cell engagers for B cell depletion in autoimmune diseases. | Nat Rev Drug Discov | 2026 | https://conductscience.org/library/papers/42844361 | PubMed |
| 42824523 | Life-Threatening Eosinophilic Granulomatosis With Polyangiitis During Omalizumab Therapy for Chronic Urticaria: Missed Diagnosis, Induction, or Unmasking? | Cureus | 2026 | https://conductscience.org/library/papers/42824523 | PubMed |
| 42806340 | Identification of clinical-biological endophenotypes in patients with eosinophilic granulomatosis with polyangiitis using unsupervised machine learning: a real-world study. | Respir Res | 2026 | https://conductscience.org/library/papers/42806340 | PubMed |
| 42797375 | Effectiveness and Safety of Rituximab in Patients with Refractory Juvenile Idiopathic Arthritis: A Tertiary Center Experience. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42797375 | PubMed |
| 42796306 | Association Between Any Circulating ANCA Positivity at Diagnosis and Subsequent End-Stage Kidney Disease in Microscopic Polyangiitis and Granulomatosis with Polyangiitis. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42796306 | PubMed |
| 42780982 | Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient With Metastatic Renal Cell Carcinoma and Limited Renal Reserve: A Diagnostic Challenge. | Cureus | 2026 | https://conductscience.org/library/papers/42780982 | PubMed |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| RITUXIMAB | CHEMBL1201576 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1201576 | ChEMBL |
| AVACOPAN | CHEMBL3989871 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL3989871 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36927642
GET https://conductscience.org/api/papers/v1/36927642/authors?page=2